相关实验视频
Updated: May 20, 2025

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.7K
默特克在异位表达,并影响扩散大B细胞淋巴瘤的生物功能
Yan Li1,2, Cunzhen Shi1, Jiazhuo Wu1
1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hematological oncology
|May 19, 2025
概括
在扩散性大B细胞淋巴瘤 (DLBCL) 中,MerTK的表达很高. 抑制MerTK抑制DLBCL细胞的生长和进展,为这种侵袭性癌症提供了潜在的新精确治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 缺乏有效的救援治疗方法.
- 确定新的治疗点对于改善DLBCL患者的治疗结果至关重要.
研究的目的:
- 研究MerTK (一种原瘤基因) 作为DLBCL治疗点的作用.
- 在临床前DLBCL模型中评估MerTK抑制的疗效.
主要方法:
- 免疫组织化学和西部涂抹,以评估DLBCL中的MerTK表达.
- 在DLBCL细胞系和异种移植模型中使用shRNA进行MerTK淘汰.
- 用UNC2025治疗,这是一个MerTK小分子抑制剂.
- 转录组测序和KEGG通路分析.
主要成果:
- 在DLBCL样本和细胞系中观察到异常高的MerTK表达.
- 抑制MerTK (Knockdown或UNC2025) 降低了DLBCL细胞的增殖,诱导了细胞亡,并导致G2/M停止.
- 抑制MerTK改变了基因表达,显著丰富了自途径,并上调了ANXA1.
- 通过增加ANXA1表达,MerTK抑制抑制了自流.
- 在DLBCL异种移植模型中,MerTK抑制在体内减少了瘤生长.
结论:
- 在DLBCL中异位表达MerTK,并驱动瘤生长.
- 向抑制MerTK在体外和体内表现出显著的抗瘤活性.
- 在DLBCL中,MerTK是准确治疗的有希望的目标.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
The Intrinsic Apoptotic Pathway
5.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K

